This Article Full Text Full Text (PDF) All Versions of this Article: 1535-7163.MCT-07-0514v1 6/12/3081    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Miranda, M. B. Articles by Johnson, D. E. Search for Related Content PubMed PubMed Citation Articles by Miranda, M. B. Articles by Johnson, D. E.

Research Articles: Therapeutics, Targets, and Development

Inhibition of Src family kinases enhances retinoic acid–induced gene expression and myeloid differentiation

Departments of ¹ Medicine and ² Pharmacology, University of Pittsburgh and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Requests for reprints: Daniel E. Johnson, Division of Hematology/Oncology, University of Pittsburgh, Room 2.18c, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213-1863. Phone: 412-623-3245; Fax: 412-623-7768. E-mail: johnsond{at}pitt.edu

Abstract

Treatment of acute promyelocytic leukemia with retinoic acid (RA) results in differentiation of the leukemic cells and clinical remission. However, the cellular factors that regulate RA-induced myeloid differentiation are largely unknown, and other forms of acute myelogenous leukemia (AML) do not respond to this differentiation therapy. A greater understanding of the molecules that positively or negatively regulate RA-induced differentiation should facilitate the development of more effective differentiation therapies. In this study, we investigated the potential role of Src family kinases (SFK) in the regulation of RA-induced gene expression and myeloid differentiation. We report that inhibition of SFKs markedly enhanced RA-induced differentiation in myeloid cell lines and primary AML cells, as assessed by flow-cytometric analysis of cell surface markers, morphologic analysis, and nitroblue tetrazolium reduction. In addition, inhibition of SFKs enhanced expression from retinoic acid receptor (RAR) target genes encoding CCAAT/enhancer binding protein (C/EBP), PU.1, intercellular adhesion molecule-1 (ICAM-1), and cathepsin D. Moreover, a constitutively active Src inhibited RAR-dependent transcription, whereas a kinase-dead Src exerted little effect. These studies provide the first demonstration that SFKs act to negatively regulate RA-induced gene expression and myeloid differentiation and suggest that the combination of SFK inhibition and RA treatment may be therapeutically beneficial in AML. [Mol Cancer Ther 2007;6(12):3081–90]

Grant support: NIH grant CA108904 to D.E. Johnson.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

³ Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

Received 8/ 6/07; revised 9/17/07; accepted 10/12/07.